tiprankstipranks
Advertisement
Advertisement

GRCE Stock Latest News

Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum
The FlyGrace Therapeutics price target lowered to $4 from $11 at Craig-Hallum
1d ago
GRCE
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen
PremiumThe Fly
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen
1d ago
GRCE
Grace Therapeutics: Buy Rating Maintained as Addressable CMC Setback Delays but Does Not Derail GTx‑104 Value Thesis
PremiumRatings
Grace Therapeutics: Buy Rating Maintained as Addressable CMC Setback Delays but Does Not Derail GTx‑104 Value Thesis
2d ago
GRCE
Grace Therapeutics Receives FDA Complete Response for GTx-104
PremiumCompany Announcements
Grace Therapeutics Receives FDA Complete Response for GTx-104
2d ago
8K
GRCE
Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104
PremiumThe Fly
Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104
2d ago
GRCE
Grace Therapeutics, Inc trading resumes
PremiumThe FlyGrace Therapeutics, Inc trading resumes
2d ago
GRCE
Grace Therapeutics issued Complete Response Letter from FDA
Premium
The Fly
Grace Therapeutics issued Complete Response Letter from FDA
2d ago
GRCE
Grace Therapeutics, Inc trading halted, news pending
Premium
The Fly
Grace Therapeutics, Inc trading halted, news pending
2d ago
GRCE
Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year
PremiumThe Fly
Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year
2M ago
GRCE
Ten new option listings and two option delistings on January 22nd
PremiumThe Fly
Ten new option listings and two option delistings on January 22nd
3M ago
AVR
INR
Grace Therapeutics Enhances Executive Severance and Change‑in‑Control Terms
PremiumCompany Announcements
Grace Therapeutics Enhances Executive Severance and Change‑in‑Control Terms
3M ago
8K
GRCE
Grace Therapeutics Reports Q2 2026 Results and FDA Progress
PremiumCompany Announcements
Grace Therapeutics Reports Q2 2026 Results and FDA Progress
5M ago
GRCE
Grace Therapeutics Announces Q2 2026 Financial Results
PremiumCompany AnnouncementsGrace Therapeutics Announces Q2 2026 Financial Results
5M ago
8K
GRCE
Grace Therapeutics reports Q2 EPS (6c) vs (30c) last year
Premium
The Fly
Grace Therapeutics reports Q2 EPS (6c) vs (30c) last year
5M ago
GRCE
Grace Therapeutics Secures $4M Through Warrant Exercise
Premium
Company Announcements
Grace Therapeutics Secures $4M Through Warrant Exercise
6M ago
8K
GRCE
Grace Therapeutics secures $4M through common warrant exercises
PremiumThe Fly
Grace Therapeutics secures $4M through common warrant exercises
6M ago
GRCE
Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial
PremiumThe Fly
Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial
7M ago
GRCE
Grace Therapeutics Secures New Patent for GTx-104
PremiumCompany Announcements
Grace Therapeutics Secures New Patent for GTx-104
7M ago
8K
GRCE
Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104
PremiumThe Fly
Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104
7M ago
GRCE
Grace Therapeutics Holds Annual Stockholders Meeting
PremiumCompany AnnouncementsGrace Therapeutics Holds Annual Stockholders Meeting
8M ago
8K
GRCE
FDA Accepts Grace Therapeutics’ NDA for GTx-104
Premium
Company Announcements
FDA Accepts Grace Therapeutics’ NDA for GTx-104
8M ago
8K
GRCE
Grace Therapeutics announces U.S. FDA accepted NDA for GTx-104 for review
Premium
The Fly
Grace Therapeutics announces U.S. FDA accepted NDA for GTx-104 for review
8M ago
GRCE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >